NASDAQ:CARA - Cara Therapeutics Stock Price, Forecast & News

Cara Therapeutics trades on the NASDAQ under the ticker symbol "CARA."

Cara Therapeutics Inc (NASDAQ:CARA) announced its quarterly earnings data on Tuesday, November, 5th. The biopharmaceutical company reported ($0.74) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.59) by $0.15. The biopharmaceutical company earned $5.79 million during the quarter, compared to the consensus estimate of $5.56 million. Cara Therapeutics had a negative return on equity of 70.35% and a negative net margin of 470.70%. View Cara Therapeutics' Earnings History.

Cara Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, March 10th 2020. View Earnings Estimates for Cara Therapeutics.

5 Wall Street analysts have issued 12 month target prices for Cara Therapeutics' shares. Their forecasts range from $22.00 to $39.00. On average, they anticipate Cara Therapeutics' share price to reach $31.83 in the next year. This suggests a possible upside of 94.6% from the stock's current price. View Analyst Price Targets for Cara Therapeutics.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cara Therapeutics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cara Therapeutics.

News coverage about CARA stock has trended negative recently, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Cara Therapeutics earned a daily sentiment score of -2.3 on InfoTrie's scale. They also assigned media coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for Cara Therapeutics.

Cara Therapeutics saw a decline in short interest in the month of December. As of December 13th, there was short interest totalling 5,410,000 shares, a decline of 6.1% from the November 28th total of 5,760,000 shares. Based on an average daily trading volume, of 689,900 shares, the short-interest ratio is currently 7.8 days. Currently, 12.8% of the company's stock are short sold. View Cara Therapeutics' Current Options Chain.

Some companies that are related to Cara Therapeutics include Amicus Therapeutics (FOLD), Karuna Therapeutics (KRTX), ChemoCentryx (CCXI), Epizyme (EPZM), Zogenix (ZGNX), ArQule (ARQL), Arena Pharmaceuticals (ARNA), Ra Pharmaceuticals (RARX), Synthorx (THOR), Aimmune Therapeutics (AIMT), Turning Point Therapeutics (TPTX), Aurinia Pharmaceuticals (AUPH), Xencor (XNCR), Prestige Consumer Healthcare (PBH) and Eidos Therapeutics (EIDX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Cara Therapeutics investors own include Lions Gate Entertainment (LGF.A), Canopy Growth (CGC), Zynerba Pharmaceuticals (ZYNE), Puma Biotechnology (PBYI), 22nd Century Group (XXII), Insys Therapeutics (INSY), Novavax (NVAX), Fate Therapeutics (FATE), GW Pharmaceuticals PLC- (GWPH) and BioMarin Pharmaceutical (BMRN).

Cara Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Assenagon Asset Management S.A. (0.16%), Mesirow Financial Investment Management Inc. (0.05%), Janney Montgomery Scott LLC (0.05%) and Exane Derivatives (0.02%). Company insiders that own Cara Therapeutics stock include Derek T Chalmers, Frederique PhD Menzaghi, Jeffrey L Ives, Joseph William Stauffer, Mani Mohindru and Scott Terrillion. View Institutional Ownership Trends for Cara Therapeutics.

CARA stock was sold by a variety of institutional investors in the last quarter, including Exane Derivatives, Janney Montgomery Scott LLC and Mesirow Financial Investment Management Inc.. Company insiders that have sold Cara Therapeutics company stock in the last year include Derek T Chalmers, Frederique PhD Menzaghi, Jeffrey L Ives, Mani Mohindru and Scott Terrillion. View Insider Buying and Selling for Cara Therapeutics.

CARA stock was purchased by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A.. View Insider Buying and Selling for Cara Therapeutics.

Shares of CARA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CARA stock can currently be purchased for approximately $16.36.

Cara Therapeutics has a market capitalization of $654.89 million and generates $13.47 million in revenue each year. The biopharmaceutical company earns $-74,010,000.00 in net income (profit) each year or ($2.06) on an earnings per share basis. Cara Therapeutics employs 55 workers across the globe.View Additional Information About Cara Therapeutics.

The official website for Cara Therapeutics is http://www.caratherapeutics.com/.

Cara Therapeutics' mailing address is 107 ELM STREET 9TH FLOOR, STAMFORD CT, 06902. The biopharmaceutical company can be reached via phone at 203-406-3700.